Nomura Securities analyst M. Ian Somaiya reiterated a Buy rating and lifted his price target on BioMarin Pharmaceutical Inc. (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View Analyst PT Change

Wedbush Raises Price Target on BioMarin Pharma (BMRN) to $139 Following 2Q Results August 5, 2015 6:44 AM Piper Jaffray Raises Price Target on BioMarin Pharma (BMRN) to $168 Following 2Q Results August 4, 2015 8:41 AM BioMarin Pharma (BMRN) Tops Q2 EPS by 2c, FY Guidance UnchangedAugust 3, 2015 4:04 PM BioMarin Announces Second Quarter 2015 Financial Results and Company UpdateAugust 3, 2015 4:02 PM